JMP keeps Human Genome at outperform, cuts target

Human Genome Sciences, Inc. was maintained by JMP Securities analyst Charles C. Duncan at a market outperform rating, but the company's price target was reduced to $15 per share from $21 per share. JMP said the company's shares were off by 30% Wednesday after investors learned of the Lymphostat-B lupus study results. While the results may look disconcerting, JMP said experts still appear positive on the drug. Shares of the Rockville, Md.-based company were down $0.62, or 6.28%, at $9.25 on volume of 13,292,838 shares versus the three-month running average of 3,264,250 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.